Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia

被引:110
作者
Robinson, Christopher J.
Johnson, Donna D.
Chang, Eugene Y.
Armstrong, D. Michael
Wang, Wei
机构
[1] Med Univ S Carolina, Dept Obstet & Gynecol, Div Maternal Fetal Med, Charleston, SC 29439 USA
[2] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29439 USA
关键词
pregnancy; preeclampsia; placenta growth factor (PIGF); soluble Fms-like tyrosine kinase 1 receptor (s-Flt1);
D O I
10.1016/j.ajog.2005.12.049
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The purpose of this study was to determine if maternal serum concentrations of placenta growth factor (PIGF) and soluble Fins-like tyrosine kinase 1 receptor (s-Flt1) are more abnormal in patients with severe preeclampsia compared with mild preeclampsia. Study design: Serum samples were collected from 32 control patients and 80 patients with mild or severe preeclampsia. PIGF and s-Flt1 concentrations were quantitated by enzyme-linked immunosorbent assay (ELISA). Results are expressed as median (Q1-Q3) unless stated otherwise. After normalization, serum markers were compared using one-way analysis of covariance (ANCOVA). Results: Patients with preeclampsia had decreased levels of PIGF (75.1 +/- 14 vs 391 +/- 54 pg/mL, P < .0001) and elevated s-Flt1 concentration (1081 +/- 108 vs 100.1 +/- 26.9 pg/mL, P < .0001) compared with the respective controls (mean +/- SEM). PIGF concentration was lower in patients with mild preeclampsia compared with severe, respectively (67 pg/mL [39-158] vs 24 pg/mL [4-57], P < .02). s-Flt1 was not different between mild and severe preeclampsia (674 pg/mL [211-1297] vs 1015 pg/mL [731-1948], P = .08). Conclusion: PIGF and s-Flt1 serum levels are abnormal in patients with preeclampsia compared with controls, but only PIGF is more abnormal in severe preeclampsia compared with mild preeclampsia. (c) 2006 Mosby, Inc. All rights reserved.
引用
收藏
页码:255 / 259
页数:5
相关论文
共 23 条
[1]  
ACOG, 2002, OBSTET GYNECOL, V99, P869
[2]   Mechanisms of angiogenesis and arteriogenesis [J].
Carmeliet, P .
NATURE MEDICINE, 2000, 6 (04) :389-395
[3]   Structure and function of placental growth factor [J].
De Falco, S ;
Gigante, B ;
Persico, MG .
TRENDS IN CARDIOVASCULAR MEDICINE, 2002, 12 (06) :241-246
[4]  
Dekker GA, 1996, J PERINAT MED, V24, P99
[5]   Endothelial dysfunction in preeclampsia .2. Reducing the adverse consequences of endothelial cell dysfunction in preeclampsia; Therapeutic perspectives [J].
Dekker, GA ;
vanGeijn, HP .
JOURNAL OF PERINATAL MEDICINE, 1996, 24 (02) :119-139
[6]  
Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41
[7]   VEGF: an update on biological and therapeutic aspects [J].
Farrara, N .
CURRENT OPINION IN BIOTECHNOLOGY, 2000, 11 (06) :617-624
[8]   ESTIMATING FETAL AGE - COMPUTER-ASSISTED ANALYSIS OF MULTIPLE FETAL GROWTH-PARAMETERS [J].
HADLOCK, FP ;
DETER, RL ;
HARRIST, RB ;
PARK, SK .
RADIOLOGY, 1984, 152 (02) :497-501
[9]   Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia [J].
Koga, K ;
Osuga, Y ;
Yoshino, O ;
Hirota, Y ;
Xie, RM ;
Hirata, T ;
Takeda, S ;
Yano, T ;
Tsutsumi, O ;
Taketani, Y .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05) :2348-2351
[10]   Circulating angiogenic factors and the risk of preeclampsia [J].
Levine, RJ ;
Maynard, SE ;
Qian, C ;
Lim, KH ;
England, LJ ;
Yu, KF ;
Schisterman, EF ;
Thadhani, R ;
Sachs, BP ;
Epstein, FH ;
Sibai, BM ;
Sukhatme, VP ;
Karumanchi, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (07) :672-683